We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Self-Administered HPV Test Helps Screen for Cervical Cancer

By LabMedica International staff writers
Posted on 09 Feb 2012
Patient-collected specimens for human papillomavirus (HPV) DNA testing detected precancerous cervical lesions with an accuracy comparable to that of liquid-based cytology (LBC) and visual inspection with acetic acid, according to a new study.

Researchers at Peking Union Medical College (PUMC; Beijing, China), Mount Sinai School of Medicine (New York, NY, USA), and other institutions worldwide reviewed patient data from five population-based cervical cancer–screening studies in China. More...
In all, 13,140 participants underwent Self-HPV testing, physician-collected cervical specimens for HPV testing, LBC, and visual inspection with acetic acid (VIA). Screen-positive women had a subsequent colposcopy and confirmatory biopsy. The researchers than analyzed the accuracies of pooled Self-HPV testing, Physician-HPV testing, VIA, and LBC to detect biopsy-confirmed cervical intraepithelial neoplasia grade 2 or more severe (CIN2+), and CIN3+.

The results showed that 3.9% of the women were diagnosed as CIN2+, 2.1% as CIN3+, and 0.3% with cervical cancer. Self-HPV testing had 86.2% sensitivity and 80.7% specificity for detecting CIN2+, and 86.1% sensitivity and 79.5% specificity for detecting CIN3+. VIA had statistically significantly lower sensitivity for detecting CIN2+ and CIN3+, and higher specificity for detecting CIN2+ and CIN3+ than Self-HPV testing, while LBC had lower sensitivity for detecting CIN2+, similar sensitivity for detecting CIN3+, and higher specificity for detecting CIN2+ and CIN3+ than Self-HPV testing. Physician-HPV testing, on the other hand, was more sensitive for detecting CIN2+ and CIN3+, but similarly specific for detecting CIN2+ and CIN3+ than Self-HPV testing.

“Although it is not specific enough to be a stand-alone test, self-HPV testing provides sensitive results without pelvic exams, medical professionals, or healthcare facilities and thus has the potential to serve as a primary cervical cancer screening method for women, regardless of their geographic location or access to healthcare,” concluded lead author You-Lin Qiao, MD, PhD, of PUMC. “Limited resources can then be focused on the clinical follow up of the smaller percentage of women who tested positive.”

One-seventh of all cervical cancers worldwide occur in China, which lacks a national screening program. Self-collected cervicovaginal specimens tested for HPV DNA could therefore effectively serve as a primary cervical cancer screening method in China and other low-resource settings.

Related Links:
Peking Union Medical College
Mount Sinai School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.